Volume 233, Issue 1 pp. 233-255

Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis

Beatrix Bartok

Beatrix Bartok

Division of Rheumatology, Allergy, and Immunology, UCSD School of Medicine, La Jolla, CA, USA.

Search for more papers by this author
Gary S. Firestein

Gary S. Firestein

Division of Rheumatology, Allergy, and Immunology, UCSD School of Medicine, La Jolla, CA, USA.

Search for more papers by this author
First published: 23 December 2009
Citations: 1,503
Gary S. Firestein
Division of Rheumatology, Allergy and Immunology
UCSD School of Medicine
9500 Gilman Dr., Mail Code 0656
La Jolla, CA 92093, USA
Tel.: +1 858 822 0480
Fax: +1 858 534 2606
e-mail: [email protected]

Abstract

Summary: Rheumatoid arthritis (RA) remains a significant unmet medical need despite significant therapeutic advances. The pathogenesis of RA is complex and includes many cell types, including T cells, B cells, and macrophages. Fibroblast-like synoviocytes (FLS) in the synovial intimal lining also play a key role by producing cytokines that perpetuate inflammation and proteases that contribute to cartilage destruction. Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage. Recent advances in understanding the biology of FLS, including their regulation regulate innate immune responses and activation of intracellular signaling mechanisms that control their behavior, provide novel insights into disease mechanisms. New agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.